EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype

Kalliopi Domvri, Ioanna Tsiouprou, Petros Bakakos, Paschalis Steiropoulos, Konstantinos Katsoulis, Konstantinos Kostikas, Katerina M Antoniou, Andriana I Papaioannou, Nikoletta Rovina, Paraskevi Katsaounou, Theodora Papamitsou, Nicoleta Pastelli und 5 weitere

Journal of Allergy and Clinical Immunology · 2025-02 · 155 (2) · 425-435

DOI: 10.1016/j.jaci.2024.10.024 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-02. Verfasst von Kalliopi Domvri und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Department, George Papanikolaou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; Laboratory of His…. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Airway Remodeling, Eosinophils. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Clinical trials and real-world experience have provided evidence for the clinical benefits of mepolizumab, an anti-IL-5 biologic, in severe asthma. However, limited data exist regarding the impact of mepolizumab on airway remodeling. OBJECTIVE: We sought to investigate the effect of mepolizumab on airway structural remodeling in patients treated for severe asthma in routine clinical care. METHODS: The MESILICO (Efficacy of Mepolizumab in patients with latE-onset Severe eosInophiLic asthma and fIxed obstruCtiOn) study is a multicenter study involving 8 pulmonology departments in Greece. This study focused on patients who initiated mepolizumab for severe asthma with an eosinophilic phenotype and had late-onset disease with obstructive patterns (impaired reversibility). Forty-seven patients were recruited, of whom 41 were enrolled in the bronchoscopy substudy. The findings were related to clinical outcome. RESULTS: After 12 months, mepolizumab treatment was associated with significant improvements in lung function and Asthma Control Test score, along with a significant decrease in severe exacerbation events (P < .001). Thirty-four of the 41 participants (83%) had paired biopsies for comparative analysis. There was a significant reduction from baseline in sub-basement membrane thickness, airway smooth muscle area, airway smooth muscle layer thickness, extent of epithelial damage, and number of tissue eosinophils (all P < .001). The extent of reduction in airway smooth muscle layer thickness positively correlated with the submucosal eosinophil reduction (r = 0.599; P < .001). CONCLUSIONS: This study identified that 12 months of mepolizumab treatment in patients with late-onset severe asthma, who are also characterized by eosinophilic and impaired reversibility phenotypes, not only leads to clinical improvement but also reduces indices of airway tissue remodeling suggestive of a disease-modifying effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedAirway RemodelingEosinophilsAnti-Asthmatic AgentsHumansMaleFemaleMiddle AgedAdultPhenotypeAgedTreatment Outcome

Stichwörter der Autor:innen

Severe asthmaairway remodelingbronchoscopyeosinophilicfixed obstructionmepolizumab

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Pulmonary Department, George Papanikolaou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; Laboratory of Histology-Embryology, School of Medicine, Aristotle University of Thessal…
  • Pulmonary Department, George Papanikolaou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • 1st Respiratory Department, Sotiria Chest Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
  • Department of Respiratory Medicine, Medical School, Democritus University of Thrace, University General Hospital Dragana, Alexandroupolis, Greece.
  • Pulmonary Department, 424 Army General Hospital, Thessaloniki, Greece.
  • Respiratory Medicine Department, University of Ioannina, Ioannina, Greece.

Förderung

  • GlaxoSmithKline Inc

Zitieren

APA

Domvri, K., Tsiouprou, I., Bakakos, P., Steiropoulos, P., Katsoulis, K., Kostikas, K., Antoniou, K. M., Papaioannou, A. I., Rovina, N., Katsaounou, P., Papamitsou, T., Pastelli, N., Tryfon, S., Fouka, E., Papakosta, D., Loukides, S., & Porpodis, K. (2025). Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype. Journal of Allergy and Clinical Immunology, 155(2), 425-435. https://doi.org/10.1016/j.jaci.2024.10.024

Vancouver

Domvri K, Tsiouprou I, Bakakos P, Steiropoulos P, Katsoulis K, Kostikas K, et al. Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype. Journal of Allergy and Clinical Immunology. 2025;155(2):425-435. doi:10.1016/j.jaci.2024.10.024

BibTeX
@article{Domvri2025,
  author = {Domvri, Kalliopi and Tsiouprou, Ioanna and Bakakos, Petros and Steiropoulos, Paschalis and Katsoulis, Konstantinos and Kostikas, Konstantinos and Antoniou, Katerina M and Papaioannou, Andriana I and Rovina, Nikoletta and Katsaounou, Paraskevi and Papamitsou, Theodora and Pastelli, Nicoleta and Tryfon, Stavros and Fouka, Evangelia and Papakosta, Despoina and Loukides, Stelios and Porpodis, Konstantinos},
  title = {Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  volume = {155},
  number = {2},
  pages = {425--435},
  doi = {10.1016/j.jaci.2024.10.024}
}
Kostenlos starten →